Charles River Laboratories Intl. Inc (NYSE:CRL) – Investment analysts at Mitsubishi UFJ Financial Group decreased their Q2 2019 earnings per share (EPS) estimates for Charles River Laboratories Intl. in a research report issued on Wednesday, February 13th. Mitsubishi UFJ Financial Group analyst J. Twizell now anticipates that the medical research company will post earnings per share of $1.62 for the quarter, down from their prior forecast of $1.63. Mitsubishi UFJ Financial Group also issued estimates for Charles River Laboratories Intl.’s FY2019 earnings at $6.45 EPS and Q1 2020 earnings at $1.53 EPS.
Get Charles River Laboratories Intl. alerts:A number of other research analysts have also recently weighed in on the company. Zacks Investment Research upgraded Charles River Laboratories Intl. from a “sell” rating to a “hold” rating and set a $156.00 price target for the company in a research report on Thursday, February 14th. Barclays restated a “hold” rating and issued a $135.00 price target on shares of Charles River Laboratories Intl. in a research report on Thursday, February 14th. SunTrust Banks raised their price target on Charles River Laboratories Intl. to $151.00 and gave the company a “buy” rating in a research report on Thursday, February 14th. Jefferies Financial Group restated a “buy” rating and issued a $162.00 price target on shares of Charles River Laboratories Intl. in a research report on Thursday, February 14th. Finally, ValuEngine cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Seven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Charles River Laboratories Intl. currently has an average rating of “Buy” and an average target price of $140.21.
Shares of CRL stock opened at $140.86 on Monday. Charles River Laboratories Intl. has a fifty-two week low of $101.58 and a fifty-two week high of $141.53. The firm has a market capitalization of $6.77 billion, a PE ratio of 23.36, a PEG ratio of 1.83 and a beta of 0.99. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.61 and a quick ratio of 1.32.
Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 13th. The medical research company reported $1.49 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.10. Charles River Laboratories Intl. had a return on equity of 24.09% and a net margin of 9.99%. The business had revenue of $605.53 million during the quarter, compared to analysts’ expectations of $589.86 million. During the same quarter last year, the business posted $1.40 earnings per share. The business’s revenue for the quarter was up 26.5% on a year-over-year basis.
A number of large investors have recently modified their holdings of the business. BlackRock Inc. boosted its stake in Charles River Laboratories Intl. by 0.4% in the 4th quarter. BlackRock Inc. now owns 4,530,012 shares of the medical research company’s stock worth $512,709,000 after buying an additional 18,491 shares during the last quarter. FMR LLC boosted its stake in Charles River Laboratories Intl. by 51.9% in the 3rd quarter. FMR LLC now owns 1,869,469 shares of the medical research company’s stock worth $251,518,000 after buying an additional 638,644 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Charles River Laboratories Intl. by 13.8% in the 3rd quarter. Renaissance Technologies LLC now owns 1,724,800 shares of the medical research company’s stock worth $232,055,000 after buying an additional 209,500 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Charles River Laboratories Intl. by 5.9% in the 3rd quarter. Wells Fargo & Company MN now owns 1,394,064 shares of the medical research company’s stock worth $187,556,000 after buying an additional 77,429 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in Charles River Laboratories Intl. by 28.0% in the 4th quarter. First Trust Advisors LP now owns 1,099,399 shares of the medical research company’s stock worth $124,430,000 after buying an additional 240,437 shares during the last quarter. 99.47% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Chairman James C. Foster sold 1,977 shares of the stock in a transaction on Monday, December 10th. The stock was sold at an average price of $129.11, for a total transaction of $255,250.47. Following the sale, the chairman now owns 267,676 shares of the company’s stock, valued at $34,559,648.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Chairman James C. Foster sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, January 8th. The stock was sold at an average price of $115.00, for a total value of $2,875,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,417 shares of company stock worth $3,590,419. Corporate insiders own 2.10% of the company’s stock.
Charles River Laboratories Intl. Company Profile
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
Read More: The risks of owning bonds
No comments:
Post a Comment